Skip to contentC
Cerenome, Inc.
C
CNSYCerenome, Inc. Q3 2024 · 10-Q
Revenue$1.46M$1.46Mno prior Q3 2023 on file Net Income-$2.87M-$2.87MN/M vs Q3 2023 EPS Diluted-$0.37-$0.37N/M vs Q3 2023 Operating Income-$3,799,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cerenome, Inc. · CIK 1095981 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,694,000N/M Margins · derivedOperating margin-260.9%
Net margin-197.4%
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end